Celiac disease is a wheat gliadin-promoted disorder that displays a complex genetic susceptibility associated with HLA-DQ2, and one or more unknown factor(s), possibly gliadin-like. The presence of mammalian proteins with partial gliadin similarity was suggested by transglutaminaseindependent multi-tissue reactivity of gliadin-immunopuri®ed antibodies from celiac patients. No non-plant sequence, however, was identi®ed in gliadin peptide epitope searches of non-redundant and EST databanks via TBLASTN, BLASTP and FASTA, even at E values as high as 20. Therefore, an a-gliadin cDNA screen of human cDNA and genomic libraries was undertaken, an approach in keeping with positive human Northern and Southern analyses with the same probe. Four distinct cDNA clones were obtained, the most stringent of which (3.2 and 5.1 kb) were novel, and featured potential open reading frames with high gliadin domain II and domain IV homologies (BestFit quality scores 5295 and 322, respectively, versus random value 126-127). Both were also homologous to ESTs. An additional 5
Introduction
Celiac disease is a disorder of the small intestine characterized by villous atrophy and crypt hyperplasia secondary to ingestion, proteolysis and intestinal absorption of wheat gliadins in genetically susceptible individuals, particularly those with HLA-DQ2 haplotype (Sollid & Thorsby, 1993) . Evidence suggests that the condition is immune mediated. Celiac disease exhibits high serum titers to gliadin and to a basement mem-brane-like connective tissue region termed endomysium (Valeski et al., 1990) ; and is estimated to affect at least 0.2-0.5 % of the population (Catassi et al., 1994) .
Gliadins comprise a large number of proteins of multigene origin (Okita et al., 1985) that may be grouped according to electrophoretic mobility into the a, b, g, and o-subfractions, all of which have been shown to be celiac-activating in vivo (Ciclitira et al., 1984) . Alternatively, gliadins may be classi®ed according to their N-terminal amino acid sequences as the a, g, and o-type gliadins (Autran et al., 1979) . Among the a-type gliadins is Aggregable-gliadin or A-gliadin, one of the ®rst gliadins sequenced (Kasarda et al., 1984) and the most extensively studied.
Experiments examining the pathogenesis of celiac disease have applied gliadin fragments and synthetic peptides in vivo or to in vitro assays of small intestinal villous atrophy and T-cell proliferation, thereby revealing disease-activating properties of various areas of the gliadin molecule. In vitro assays have suggested that peptides from the N-terminal domain of A-gliadin (Kasarda et al., 1984) may cause villous atrophy (De Ritis et al., 1988; Wieser et al., 1986; Maiuri et al., 1996; Shidrawi et al., 1995) . Of these, A-gliadin residues 31-49 also promoted proliferation of a DQ2-restricted T-cell clone from the peripheral blood of a patient with celiac disease , and caused in vivo histological relapse of small intestinal lesions in four celiac patients (Sturgess et al., 1994) . In vivo challenge with a peptide from the C-terminal domain of A-gliadin has yielded con¯icting results (Mantzaris & Jewell, 1991; Sturgess et al., 1994) , although a similar peptide caused proliferation of a celiac patient T-cell clone originating from the small intestine (van de Wal et al., 1998a) . Also implicated in disease activation are g-gliadin (Fluge et al., 1994; Molberg et al., 1998) and o-gliadin (Ensari et al., 1998) peptides. Recently, it has become apparent that deamidation of certain glutamine residues to glutamic acid via stomach acid (Hamada, 1994) or intestinal subepithelial tissue transglutaminase leads to enhanced T-cell proliferative responses (van de Wal et al., 1998b; Sjo È stro È m et al., 1998; Quarsten et al., 1999; Anderson et al., 2000; Arentz-Hansen et al., 2000) , in keeping with reports of elevated tissue transglutaminase in celiac disease (Bruce et al., 1985) . Apparently differing are early studies linking gliadin deamidation with loss of toxicity (reviewed by Marsh, 1992) . Tissue transglutaminase, a general marker of tissue degeneration augmented in Alzheimer's (Kim et al., 1999) and Huntington's disease (Karpuj et al., 1999) , bears the additional role of autoantigen in antiendomysial immunostaining (Dieterich et al., 1997) , although additional potential autoantigens claimed to bear short sequence homology to gliadin have also been suggested (Karska et al., 1995; Bo È rner et al., 1996; Krupickova et al., 1999) , including BM180 (Laurie et al., 1995) an extracellular matrix component with a role in regulated tear secretion (Laurie et al., 1996) .
The strongly heritable nature of celiac disease is intriguing. A 70-100 % disease concordance in monozygotic twins and 10 % prevalence in ®rst-degree relatives (Sollid & Thorsby, 1993) can be linked strongly to the HLA locus on chromosome 6, an observation attributable to the very high prevalence (590 %) of DQ2 positive individuals in the celiac patient population. Since 20-25 % of normal individuals possess the HLA-DQ2 allele, some have proposed that celiac disease is initiated by a non-HLA disease gene(s) in a DQ2-positive environment (Petronzelli et al., 1997; Houlston et al., 1997; Brett et al., 1998; Greco et al., 1998; Bevan et al., 1999) . This is in keeping with weaker apparent linkage to proposed non-HLA risk factors in the terminal portions of chromosomes 5 and 11 (Greco et al., 1998) , or on chromosome 2 (Holopainen et al., 1999) among other proposed risk factors (chromosomes 6p, 11p, 7q, 22, 15q, 19; Zhong et al., 1996) . Identi®cation of such factors, possibly gliadin-like, is dif®cult and they remain unknown. Here, we report on the identi®cation and cloning of several novel and known human genes with partial, but particularly high, homology to gliadin. Mutation of glutamine to glutamic acid (or other residues) in T-cell-like epitopes of such intestinal gliadin-like molecules could explain familial susceptibility in celiac disease.
Results
Ingestion of wheat gliadin provokes an acute HLA-DQ2-linked immune response in celiac patients, manifested partially by the transient generation of both anti-transglutaminase and anti-gliadin antibodies . We puri®ed anti-gliadin antibodies from sera of affected individuals on a gliadin-Sepharose column and tested them by ELISA for cross-reactivity with EDTA or GuHCl extracts of several different mouse organs (Table 1) . The presence of both IgA and IgGattributable reactivity was apparent in all organs examined, even brain. Small intestine displayed moderate IgA-antigliadin and higher IgG-antigliadin titer (Table 1) that was partially but not completely inhibitable with soluble tissue transglutaminase (63 % versus 84 % inhibition for coated extract versus coated transglutaminase), a result complicated by the moderately impure nature of this commonly utilized (Dieterich et al., 1997 Sulkanen et al., 1998) commercial preparation. In contrast, reactivity with ELISA wells coated with gliadin was unaffected by soluble tissue transglutaminase, but partially inhibited by soluble gliadin (not shown). Indeed, recent epitope mapping of similarly puri®ed celiac patient antibodies revealed binding speci®city for a-gliadin (Kasarda et al., 1984) peptides: (i) QEQVPLVQQQQF, (ii) QILQQILQQQLI, (iii) WQIPEQSQCQAI and (iv) ALQTLPAMCN-VYIPPYCT (Krupickova et al., 1999) . Peptide (i) is located in gliadin domain I (dodecapeptide repeat; see Figure 1 for gliadin domain structure), whereas peptides (ii), (iii) and (iv) derive from domains II (®rst polyglutamine repeat), III (low proline/high histidine) and V (high proline), respectively. We tested monoclonal antibody KG9 prepared against amino acid residues 206-217 of a-gliadin (Ellis et al., 1992; peptide (v) ). All GuHCl organ extracts were stained, in contrast to a more selective pattern for EDTA extracts (lachrymal, strong; intestine, lung and kidney, moderate; and all others weak or absent; not shown). KG9 immunoreactivity was attributable to a 180 kDa band (Laurie et al., 1995) in Western blots of a mouse basement membrane extract. Taken together, such gliadin-speci®c organ reactivity points to the presence of gliadin-like motifs in mammalian tissues, a result not previously appreciated in earlier studies in which whole patient serum was commonly used.
Repeated search of peptide sequences (i) to (v) against non-redundant and EST databanks via TBLASTN, BLASTP and all DNA databases via FASTA, revealed no non-plant homology, even when E values as high as 20 were accepted. Homology between calreticulin and gliadin had been suggested (Karska et al., 1995) , particularly between EPPVIQNPEY (calreticulin) and peptide sequence (i) (Krupickova et al., 1999) . Indeed, interpeptide BestFit quality scores differed somewhat from random (quality 44 versus random quality of 30 AE 2.6, average of ten randomizations, however no regional homology was found between full-length gliadin and calreticulin, (quality 20 versus 18 AE 2.5 random). Since full-length a-gliadin cDNA hybridizes with several bands in mouse Northern, and mouse or human Southern blots at approximately 28-31 deg. C below its t m (Laurie et al., 1995) , a screen of human cDNA and genomic libraries was initiated. Full-length a-gliadin cDNA (probe VI; Figure 1 ) and an N-terminal 39-mer oligonucleotide ( Figure 1 ) were used as probes. Five cDNA clones were identi®ed with the a-gliadin cDNA probe and 14 with the oligonucleotide probe. Of the ®ve a-gliadin-screened clones, 2a and 3a were found to be identical. Whereas 2a/3a and 5a hybridized with a-gliadin probe at moderate to high criteria (t m À 15 deg. C; Figure 2 Figure 1 . The a/b-gliadin domain structure and design of cDNA probes. Top, signal peptide (signal pep) is followed by domain I (tandem repeat of a conserved dodecapeptide (dodecapep), also known as repetitive sequence), domain II (polyglutamine stretch (polyglut)), domain III (low proline/high histidine (pro/his), also known as unique sequence domain), domain IV (polyglutamine stretch (polyglut), and domain V (high proline (pro), also known as unique sequence domain) (Kasarda et al., 1984; Okita et al., 1985) . Below is the corresponding mRNA with 5 H and 3 H untranslated regions, both of which are conserved among gliadins. Middle, 39-mer oligo probe corresponding to the gliadin-identical N terminus of BM180 (Laurie et al., 1995) as BackTranslated using the human (highly expressed) genes codon frequency table. Bottom, cDNA probes including complete gliadin cDNA (probe VI), and several partial cDNA (probes I -V) approximately corresponding to individual gliadin domains (I , signal peptide plus domain I; II IV, domains II and IV; III, domain III; V , high proline plus some 3 H untranslated). ut-N and ut-C, 5
H and 3 H untranslated regions, respectively. Partial cDNAs were generated by restriction digestion and puri®ed. Domains II and IV could not be separated because size was similar. and feature several small potential open reading frames, some identical (AA682426, 411 bp, 2a/3a) or highly similar to EST's. Particularly striking in each was a potential open reading frame with high gliadin domain II and domain IV homology. BestFit quality scores for 2a/3a versus domains II and IV were 295 and 322, respectively (versus random value 126 AE 15 and 127 AE 19). Equivalent scores for 5a were 297 and 333 (versus random value 130 AE 17 and 124 AE 14). Homology with other gliadin domains was not signi®cant. In contrast, oligonucleotide clones 12 and 15 corresponded to known sequence ( Figure 3 ). Clone 12 was brain acyl coA hydroxylase (D88894; U91316), with a region of good homology to the oligonucleotide probe (BestFit quality 215 versus 100 AE 15 for random), but not to other gliadin domains. Clone 15 was achaete scute homologous protein (ASH1; L08424) with particularly high homology to gliadin domain II (BestFit quality 316 versus 111 AE 13 for random), and lesser homology for domain IV (173 versus 100 AE 13) and oligonucleotide probe (193 versus 101 AE 15). Achaete scute homologous protein is a helix-loop-helix transcription factor. Common among other oligonucleotide clones, including 3, 4, 8, 13 and 16, was a region of high Alu (U18391) homology, in keeping with an AluI site in the 5
H region of a-gliadin from which the oligonucleotide was derived. Clone 4 also contained part of the pro®lin II (L10678) open reading frame, but no gliadin homology was detected by BestFit. We next screened a human genomic library using a-gliadin cDNA as probe; 16 clones were identi®ed and examined by Southern analysis with a-gliadin cDNA (Figure 4 ). All but six were detected at high stringency (t m À 5 deg. C; Figure 4 (c)) with sizes of positive fragments varying from one (clone 2) to approximately nine kilobases (clone 11). Southern analyses ( Figure 5 ) were carried out with domain-speci®c probes (Figure 1) . No fragment was detected with probes ut-N (5 H untranslated; Figure 5 (a)) or III (low proline/ high histidine; Figure 5(d) ). In contrast, hybridization with one or several fragments was apparent with probes I (signal peptide plus dodecapeptide; Figure 5 (b)), II IV (polyglutamine; Figure 5 (c)), V (high proline plus some 3 H untranslated; Figure 5 (e)), and ut-C (3 H untranslated; Figure 5 (f)). Displaying the most extensive apparent gliadin homology was clone 2, whose fragments hybridized with probe I , II IV, V , and ut-C. Less extensive but still remarkable were clones 5, 7, and 12 (probes II IV, V , ut-C), 8, 11, 13, 15, and 16 (probes II IV, ut-C), 3, and 9 (II IV), and 4, and 6 (ut-C). Although several of these clones could be logically pursued further, we narrowed our efforts to two positive fragments from clone 2, and one each from clones 8 and 12. Both clones 2 and 8 contained novel sequence, whereas the positive clone 12 fragment corresponded in part to the All1-Related (ALR) gene (AF010404). BestFit comparison of ALR (15.8 kb; Prasad et al., 1997) and gliadin mRNA revealed considerable homology in the region spanning ALR residues 10861-11093 (BestFit quality 604 versus 153 AE 11 for random), particularly for gliadin domains I (473 versus 154 AE 22 for random), II (398 versus 121 AE 13 for random) and IV (322 versus 129 AE 13 for random).
To search for exons in clones 2 and 8 ( Figure 6 ), four different gene-predicting programs were used. No exon was apparent in the clone 8 fragment, nor in the larger positive fragment of clone 2 (not shown). In contrast, the smaller clone 2 fragment Gliadin Screen of Human Genome has two likely exonic regions ( Figure 6 ) on either plus or minus strands. Suggested on the minus strand by FGENES 1.6 (Solovyev et al., 1995) are internal and terminal exons at 1967-2046 (weight 1.58) and 565-769 (weight 2.19; top arrowheads, Figure 6 ), respectively. In contrast on the plus strand, Genescan (Burge & Karlin, 1997;  Figure 6 , short arrow) predicts a plus strand terminal exon at 1961-2126 and a poly(A)signal at 2228-2233 (total score 17.5; probability 0.965). A similar 1962-2119 plus strand prediction is made by Grail 2 (Uberbacher et al., 1996 ; score 100; quality excellent; open arrowhead, Figure 6 ), the latter of which corresponds to a gliadin-like region (BestFit quality 373 versus 137 AE 19 for random) with particular homology to domains I (228 versus 121 AE 12 for random), II (319 versus 118 AE 16 for random) and IV (365 versus 102 AE 9 for random). Also predicted are two minus strand exons at 376-480 and 526-687 (score 51 and 61, respectively; quality good; Grail 2); a minus strand internal exon at 554-742, as well as a minus strand initial exon 1671-1673 (combined score 96.8; Genie (Reese et al., 1997) ); and plus strand initial (905-954) and internal exons (2626-2683; combined score 96.3; Genie).
We designed oligonucleotide probes complementary to plus or minus strands from each predicted exonic region and checked each by BLAST to verify lack of recognition with existing sequences in the non-redundant and EST databases. Application to a poly(A) RNA dot blot representing 50 different human tissues, with high stringency washes revealed the strongest speci®c labeling for probe a (t m À 8.8 deg. C; nucleotides 655-627) over a number of different tissues (Figure 7 , ®lled bars and lower inset). By contrast, control RNAs (yeast total RNA and tRNA; Escherichia coli rRNA) and DNAs (E. coli DNA; human Cot1 and genomic DNA) were blank (Figure 7 , dots H1 to H8). Probe b (t m À 12.1 deg. C; nucleotides 620-644) from the opposite strand displayed some hybridization with uterus RNA, but little elsewhere (Figure 7 , open bars). No expression was detected with probes c and d (not shown). Examination of probe a-labeled Northern blots pointed to message sizes of 4 and 2 kb (human liver; Figure 7 , top inset; human adrenal gland, trachea, lymph node, spinal cord, thyroid and stomach; not shown), or only 4 kb (human lung; Figure 7 , top inset). Longer exposure revealed additional 5.8 kb, 1.4 kb (liver) and 0.8 kb (lung) messages (not shown). Some smearing was apparent in bone marrow, kidney and brain (not shown). FISH revealed that clone 2 maps to chromosome 19 (Figure 8(a) ), a result con®rmed by double labeling with a probe for the E2A locus of 19p13 (Figure 8(b) and (c), small arrows). Analysis of ten speci®cally labeled chromosomes located clone 2 approximately 23 % of the distance from the centromere to the telomere of chromosome arm 19q, an area that corresponds to band 19q13.11-13.12 (Figure 8(d) ).
Discussion
Celiac disease is a complex disorder whose suspected non-HLA risk factor(s) remains unknown. Building on observations of patient anti-gliadin cross-reactivity with mammalian proteins and prior hybridization of a-gliadin cDNA to human Southern and Northern blots (Laurie et al., 1995) , we searched for human genes with strong homology to one or several of wheat gliadin's seven domains. Highly homologous to domains II and/ or IV were novel EST-containing cDNAs 2a/3a and 5a, and a cDNA (clone 15) corresponding to the transcription factor achaete homologous protein. Similarly, acyl coA hydrolase (clone 12) was identi®ed as having similarity to a domain I oligonucleotide probe, but not other domains. More extensive gliadin homology was displayed by genomic clones, particularly novel clone 2 (domains I, II IV, V and 3 H untranslated region) and All1-Related (ALR) gene (clone 12; domains II IV, V, 3 H untranslated region), the former of which was pursued by stepwise subcloning, sequencing, exonic analysis, application of test oligonucleotides and FISH, thereby revealing expression as 4 and 2 kb mRNAs in a wide variety of human tissues including small intestine, and mapping to chromosome 19q13.11-13.12. (a, 655-627; b, 620-644; c, 1987-1962; d, 1952-1968) corresponding each of these two regions were synthesized, labeled and applied to Northern blots; a was particularly successful ( ).
Various methods were used to ensure speci®city in hybridization and homology searches. Final Northern and Southern blot wash stringencies were high, typically within À8.8 to À5 deg. C of the t m . BLAST and FASTA searches utilized SeqWeb default settings, and BestFit analyses were interpreted in the context of random quality values (Lipman et al., 1984) , the latter determined from ten randomized alignments of the shuf¯ed test sequence. Finally, our study of genomic sequences took advantage of four different software programs, each with documented exon prediction accuracy exceeding 77 % (Solovyev et al., 1995; Burge & Karlin, 1997; Uberbacher et al., 1996; Reese et al., 1997) .
Earlier reports of gliadin-like proteins in the mammalian domain include orangutan proteins of 32, 40 and 45 kDa that were recognized by antigliadin but not anti-endomysial or reticular antibodies in celiac patient sera; and whose N-terminal ten amino acid residues or adjacent sequences (Bo È rner et al; 1996) displays 80-100 % identity with a/b (P04721, P04722, P04726) or g (P06659) gliadins. Overall, gliadin BestFit quality (39-55) generally exceeds random (19-31 AE 2-4), an observation that is true, in part, for two human proteins identi®ed in a FASTA search with each peptide: (i) basigin precursor (P35613; BestFit quality 31 versus 18 AE 3; comparison to reported sequence NMQADPSGQV from 32 kDa); and (ii) YES-associated protein (P46837; BestFit quality 40 versus 25 AE 2; comparison to reported sequence PSQPQPQGQV also from 32 kDa). Yet beyond this region the latter two proteins display little or no gliadin homology (33 versus 28 AE 2 and 90 versus 60 AE 10, respectively). The calreticulin sequence EPPVIQNPEY was reported as bearing homology to gliadin, in keeping with reported celiac sera recognition of calreticulin (Karska et al., 1995; Krupickova et al., 1999) . However, BestFit quality values versus a/b or g-gliadins were all at or below background (18-22 versus 23-25 AE 3-4); or somewhat above background versus a short a/b-gliadin peptide, as indicated in Results. In contrast, the same analysis of the N-terminal BM180 sequence from mouse bears a more sub- stantial result (BestFit quality 70 versus 29 AE 4) supported by recognition of immunopuri®ed BM180 via a monoclonal anti-gliadin antibody whose peptide antigen differs from the N-terminal sequence (Laurie et al., 1995) . Although the use of an oligonucleotide corresponding to the latter was signi®-cantly limited by high G C content and a gliadin Alu site, achaete homologous protein (L08424) and acyl coA hydrolase (U91316) cDNAs emerged, are widely expressed (based on cDNA sources; small intestine not examined) and bear short protein homology to BM180: PQPQPQQP (L08424) versus PQLQPQNP (BM180) (BestFit 33 versus 21 AE 4); and LPVPQLVPE (U91316) versus VPVPQLQPQ (BM180) (BestFit 35 versus 24 AE 4). More fruitful was gliadin cDNA as a probe, by which genomic clone 2, ALR gene and several other genomic clones were identi®ed. Clone 2 gliadin homology was striking, a quality prompting further analysis, including demonstrated expression in intestine and other human tissues. Identi®cation of the complete coding sequence together with protein expression studies could prove particularly rewarding should the homology be maintained at the protein level, as it is for the widely expressed ALR gene (AF010404).
Do other gliadin-like proteins exist? No nonplant protein was homologous to dodecapeptide or larger anti-gliadin antibody epitopes (see Results). However, we identi®ed ten others in a recent a/bgliadin TFASTX search of the primate database, further narrowed by BestFit analysis of each translated match using the a/b-gliadin protein sequence as probe. Above random matches (145-182 versus random 43-107) include: AB024075/AB001895 (B120), AB028971 (KIAA1048), Z50194 (PHLDA1), U80741/U80742 (CAGH44/45), U91935/U91934 (retina-derived POU-domain factor-1), D83783/ AF117755/AF071309 (KIAA0192 or TRAP230), U80231 (H65), AJ251016 (SK3), AF089824 (NFAT5), and D80003/AF177388/AF208227 (KIAA0181/ AIB3/ASC-2). Also identi®ed was ALR. Analyzed at the nucleic acid level using a/b-gliadin cDNA as the probe, the mean BestFit score was 429 versus 140 AE 13 for random; with highest scores for U80741/U80742 and D83783, in which domain I, II and IV homologies were particularly strong. Taken together, it is apparent that cDNA clones 2a/3a, 5a, brain acyl coA hydroxylase, achaete scute homologous protein, genomic clones 2 and ALR, as well as BM180 and the genes identi®ed above, share a unique level of gliadin homology, a relationship that may bear on celiac disease susceptibility, possible via rare mutation.
Prior search for non-HLA risk factors has utilized linkage analysis, a powerful and potentially de®nitive approach that, in the face of apparent disease complexity (Bevan et al., 1999) , possibly compounded by use of different population samples, has proven dif®cult to replicate. Thus, Zhong et al. (1996) drew attention to 12 potential linkage regions (3q27, 5q33.3, 6p23, 6p21.3, 6p12, 7q31.3, 11p11, 15q26, 19p13.3, 19q13.1, 19q13.4 , and 22cen) in a 15 family Irish group. None, however, was apparent in two independent replicative attempts based on UK family groups of slightly larger size (Houlston et al., 1997; Brett et al., 1998) , with the possible exception of a suggested weak association at 15q26 (Houlston et al., 1997) . A larger (105 families) Italian whole-genome analysis (Greco et al., 1998) pointed to a potential risk factor in 5qter (in possible agreement with 5q33.3), and a second 11qter factor proposed to distinguish between symptomatic and silent celiac disease. No other association, however, was apparent. Limited attempts to link celiac diseases with known genes (T-cell receptor delta, Roschmann et al., 1996; TNF 1-3, McManus et al., 1996; CD28/CTLA4, Holopainen et al., 1999) have found no (T-cell receptor) or some suggestive (TNF and CD28/ CTLA4) evidence. However, TNF 1-3 and HLA share 6p21.3, thereby signi®cantly complicating analysis, and CD28/CTLA4 (2q33) is not speci®c for celiac disease. Linkage analyses with a wider pool of candidate genes including the gliadin-like genes now identi®ed may prove fruitful. Some of the latter have been mapped as follows: brain acyl coA hydroxylase, chrs 1; achaete scute homologous protein, 12q22-q23; genomic clone 2 (this study), 19q13.11-12.12; ALR, 12q12-q14; AB024075/ AB001895, 1p36.1-p35; U91935, 7p13-p14; D83783/ AF117755/AF071309, Xq13; AF089824, 16q22.1, D80003/AF177388/AF208227, 20q11.
Recent advances have pointed to tissue transglutaminase as a key target of anti-endomysial antibodies (Dieterich et al., 1997) and as an agent in the intestinal deamidation of dietary gliadin, the latter of which potentiates binding and proliferation of DQ2- , 1998b) , or the glutenin epitope QGYYPTSPQQS (DQ8; deamidation decreases activity; van de Wal et al., 1999) tentatively suggests that all except brain acyl coA hydroxylase, U80231 and AF089824 may have this potential. Most similar were D80003/ AF177388/AF208227 (QPQPQLPQQQ and PQPP QQQPQPQLP versus T-cell epitopes QPQQ SFPQQQ and PQPQLPYPQPQLPY, respectively), and Z50194 (PQPQLQPQPQPQ versus T-cell epitope PQPQLPYPQPQLPY); with corresponding BestFit quality scores of 38, 49 and 48 versus random scores of 28 AE 4, 33 AE 5 and 34 AE 3, respectively. D80003/AF177388/AF208227 and Z50194 are known to be expressed in the small intestine or colon, mainly intracellularly as is tissue transglutaminase. Seven other candidate proteins were identi®ed in stringent FASTA searches using each T-cell epitope as probe. Most noteworthy were X92850 (Pax 9; QHQPTPQPALPY versus QLQPFPQPQLPY; BestFit score 48 versus random score of 21 AE 1.5) and AK000266 (unnamed; QPQQQTPQEQ versus QPQQSFPQQQ; BestFit score 39 versus random score of 23 AE 4). Both are cytoplasmic and expressed in the forestomach (X92850) or colon (AK000266). Among all protein sequences, homologies are curiously restricted to DQ2 T-cell epitopes, with the exception of a glutenin-like DQ8 epitope in M81840/U95012 (quality score 41 versus 17.5 AE 3). Finally, it is apparent that codon usage for one-half of the highlighted sequences is such that single or double-point mutation is suf®cient to profoundly enhance T-celllike epitope homology. Exacerbated by viral or bacterial infection or dietary gliadin, the release of intestinal intracellular transglutaminase and gliadin-like proteins could go hand in hand. Should an inherited or newly acquired mutation in the latter enhance T-cell recognition (including Q to E), early immunological sensitization of HLA-DQ2 positive children to dietary gliadin could result. If so, alteration of different gliadin-like molecules in different celiac patients may explain replicative dif®culties in non-HLA linkage analyses.
In summary, gliadin library and database screening in conjunction with hybridization and sequence analysis has led to the discovery of a small group of gliadin-like proteins that bear remarkable homology to one or several gliadin domains. Particularly striking was genomic clone 2 and the ALR gene, in which representation by gliadin domains was the most extensive. We propose that intestinal gliadin-like proteins with sequence similar to gliadin T-cell epitopes, possibly enhanced by selective mutation(s), may be involved in celiac disease initiation.
Materials and Methods

ELISA
Gliadin af®nity columns (8.6 mg gliadin/ml of gel) generated by coupling gliadin (dissolved in 0.1 M acetic acid; Fluka, Buchs Switzerland) to Aminolink (Pierce, Rockford, IL) at pH 4, were incubated overnight at 4 C with pooled sera (0.5-1.5 ml/ml column) from 10-12 celiac patients on a normal gluten-containing diet. After extensive washing, bound human anti-gliadin antibodies were eluted with 1 % (w/v) triethylamine (pH 10), PBSwashed and concentrated on Centricon-10 ®lter devices (Pierce, Rockford, IL). Celiac patients comprised ®ve males aged 34 to 90 years (mean 56.5 years) and seven females aged 15 to 46 years (mean 33.9 years). All were anti-endomysial antibody positive, had clinical symptoms suggestive of malabsorption and on duodenal biopsy were judged by a histopathologist to have changes in keeping with celiac disease. A gluten-free diet later led to an improvement in clinical symptoms and resolution of duodenal histology towards normal.
EDTA/EGTA and GuHCl extracts of four weeks old mouse intestine, brain, lung, kidney, pancreas and lachrymal gland, and adult parotid were sequentially prepared at 4 C as described (Laurie et al., 1996) . For ELISA, wells were coated overnight (4 C) with EDTA or GuHCl extracts or with tissue transglutaminase (Sigma, St. Louis MO) or gliadin (Fluka), all diluted in carbonate/bicarbonate buffer and applied at 10 mg/cm 2 . Wells were blocked with PBS containing 0.01 % (v/v) Tween-20, washed and then incubated overnight (4 C) with af®nity-puri®ed human anti-gliadin antibodies diluted 1/100 in PBS-Tween containing 1 % (w/v) bovine serum albumin. Detection was with peroxidase-labeled secondary antibodies (Jackson Immunoresearch, West Grove, PA) diluted 1/1000 followed by ABTS-H 2 O 2 . Values were recorded at 405 nm using a Molecular Devices plate reader (Menlo Park, CA). In competition experiments, diluted antibodies were preincubated for one hour at 4 C with soluble tissue transglutaminase (50 mg/ml) or gliadin (100 mg/ml) prior to addition to intestinal EDTA extract-coated, tissue transglutaminasecoated or gliadin-coated wells.
cDNA probe preparation
Full-length a-gliadin cDNA (1.1 kb, clone A212, M10092; Okita et al., 1985 originally provided by Dr T. Okita, Washington State University, Pullman, WA, then subcloned into pBluescript; Laurie et al., 1995) was gel-puri®ed and used intact (probe VI), or subdivided by restriction digestion into fragments corresponding to gliadin's ®ve domains (Figure 1 ). Also prepared were 5 H and 3
H untranslated region fragments. Advantage was taken of strategically placed restriction sites identi®ed by DNA sequence analysis. Sequential triple digestion with BanI, ApoI and BsiHKAI (New England Biolabs, Beverly, MA) produced probes ut-N (48 bp; 5 H untranslated region) and III (153 bp; domain III), and two similarsized fragments representing domains I II (420 bp) and domains IV V plus the 3 H untranslated region (481 bp) that were gel-puri®ed together. Digestion of the latter two fragments with Bst4CI (Sibenzyme, Novosibirsk, Russia) generated probes I (332 bp; signal peptide domain I), V (266 bp; domain V plus 40 bp of 3 H untranslated region) and ut-C (126 bp; remainder of 3 H untranslated region). Similar-sized probes II and IV (84 and 93 bp; domains II and IV, respectively) were puri®ed together. A 39-mer oligonucleotide corresponding to the ®rst 13 amino acids of domain I (and the BM180 N-terminal sequence; Laurie et al., 1995) was synthesized. cDNA probes were labeled by random priming in the presence of [ 32 P]dCTP (3000 Ci/mmol; ICN, Irvine, CA) and puri®ed with nick-spin columns (Pharmacia, Piscataway, NJ). The oligomer probe was endlabeled using polynucleotide kinase in the presence of [g 32 P]ATP (7000 Ci/mmol; ICN, Irvine, CA) and similarly puri®ed.
Library screening and Southern analysis
Probe VI screening of human fetal brain cDNA (in lUni-ZAP XR; Stratagene, La Jolla, CA) and human HT1080 genomic (in lDASH II; Stratagene) libraries was performed by standard methods. Filter-adsorbed plaques were probe-hybridized overnight at 42 C in 5 Â SSPEcontaining buffer (SSPE is 150 mM sodium chloride, 10 mM sodium phosphate, 1 mM EDTA), washed three times at room temperature in 2 Â SSC, 0.1 % (w/v) SDS, washed once (55 C) or three times (42 C) in 0.1 Â SSC, 0.1 % SDS, and then exposed to X-ray ®lm. Oligo probe screening of the human fetal brain cDNA library was performed using similar hybridization and initial wash conditions, but with a ®nal 60 C wash in 2 Â SSC, 0.1 % SDS. Picked positives were rescreened two more times to clonality and restriction-digested with EcoRI and XhoI (cDNA) or EcoRI and BamHI (genomic). Genomic digests were subjected to Southern analysis with probe VI at increasing wash stringency (45 , 55 and 65 C in 0.1 Â SSC, 0.1 % SDS). Overnight X-ray ®lm exposure was performed after each wash step. Similarly prepared genomic blots were hybridized with domain-speci®c probes and washed in 0.1 Â SSC, 0.1 % SDS at 45 C (ut-N, I , III and ut-C) or 50 C (II, IV and V). Promising cDNA clones or genomic fragments were excised as pBluescript (cDNA), or gel-puri®ed and ligated into pBluescript (genomic) for further analysis.
Sequencing and sequence analysis
Intact or nested deleted inserts were sequenced by T3 or T7-priming and primer walking via a Prizm 377 DNA Sequencer (Perkin-Elmer, Branchburg, NJ; UVa Biomolecular Research Facility). Both strands were sequenced completely. Editing and alignment of sequences used Unix-based Seqed and Gelstart software (Genetics Computer Group, Madison, WI). Subsequent analysis of consensus sequence took advantage of web-based Seqweb (Genetics Computer Group) for BLAST, FASTA (NCBI, Bethesda MD) and BestFit analyses, all at default settings. cDNA open reading frames were revealed using ORF ®nder at the National Center for Biotechnology Information web site. Exon searching of all sequenced genomic fragments was facilitated by the Baylor College of Medicine Human Genome Sequencing Center web site with web-based software for FGENE 1.6 (Solovyev et al., 1995) , Genescan (Burge & Karlin, 1997) , Grail 2 (Uberbacher et al., 1996) and Genie (Reese et al., 1997) .
Data Bank accession codes
All sequences have been submitted to GenBank with accession numbers: AF238870 (2a/3a cDNA), AF2238869 (5a cDNA), AF238868 (smaller genomic clone 2 fragment), AF238872 and AF238873 (larger genomic clone 2 fragment), and AF238871 (genomic clone 8 fragment).
Northern analysis
To examine whether predicted exons were expressed, a purchased dot blot containing 50 different human poly(A) RNAs and two Northern blots with multiple human fetal and adult poly(A) RNAs (Clontech Labs, Palo Alto, CA) were hybridized (Laurie et al., 1989) with forward and reverse oligonucleotides corresponding to each putative exon from genomic clone 2 fragment. Oligonucleotides were designed via Oligo 4.04 software (National Biosciences, Plymouth, MN) and checked for lack of hybridizable homology with all nucleotide sequences in the human non-redundant and EST databases. Melting temperatures were: 58 C (in 2 Â SSC), 59
C (in 0.3 Â SSC), 61 C (in 0.3 Â SSC) and 69 C (in 0.3 Â SSC), for probes a-d, respectively. After hybridization overnight, blots were washed 50 C, 2 Â SSC (probe a), 52 C, 0.3 Â SSC (probe b), (c) 52 C, 0.3 Â SSC, or (d) 60 C, 0.3 Â SSC, and exposed to X-ray ®lm. Dot blots were then quanti®ed using NIH Image by measurement of pixel gray values of individual dots. Values were expressed in arbitrary units minus the blot background.
Chromosome mapping FISH mapping of genomic clone 2 was carried out by Genome Systems (St. Louis, MO). Puri®ed clone 2 DNA was labeled with digoxigenin dUTP by nick translation and hybridized (50 % (v/v) formamide, 10 % (w/v) dextran, 2 Â SSC) to metaphase chromosomes from phytohemagglutin (PHA)-stimulated human peripheral blood lymphocytes. Following washes, speci®c labeling was detected with¯uoresceinated antidigoxigenin antibodies and DAPI (4 H ,6-diamidino-2-phenylindole), and examined in a Nikon Labophot microscope. For con®r-mation, a double labeling experiment was performed using a known chromosome 19 telomere-speci®c marker from the E2A locus. A total of 80 metaphase cells were analyzed, with 73 exhibiting speci®c labeling. Photographs were taken on a Nikon AFX at a ®nal magni®-cation of 1435 Â.
